Humana (NYSE:HUM) PT Lowered to $326.00

Humana (NYSE:HUM) had its price target lowered by UBS Group from $334.00 to $326.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a “neutral” rating on the insurance provider’s stock. UBS Group’s price objective points to a potential upside of 6.57% from the company’s previous close.

Several other research analysts have also recently commented on HUM. Barclays decreased their target price on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a report on Tuesday, April 2nd. Argus downgraded shares of Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 13th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $391.00 target price on shares of Humana in a research report on Wednesday, April 10th. TD Cowen dropped their price target on Humana from $427.00 to $396.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Finally, StockNews.com cut Humana from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 26th. Eleven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $433.74.

Humana Trading Down 1.8 %

Shares of NYSE:HUM opened at $305.91 on Thursday. The stock has a market capitalization of $36.91 billion, a price-to-earnings ratio of 19.05, a PEG ratio of 1.85 and a beta of 0.45. Humana has a 1-year low of $299.23 and a 1-year high of $541.21. The company has a 50 day moving average price of $327.77 and a 200 day moving average price of $394.49. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.59 and a current ratio of 1.67.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The business had revenue of $29.61 billion for the quarter, compared to analysts’ expectations of $28.52 billion. During the same period in the previous year, the firm posted $9.38 EPS. The company’s quarterly revenue was up 10.7% on a year-over-year basis. On average, research analysts anticipate that Humana will post 16.06 EPS for the current fiscal year.

Insider Transactions at Humana

In other Humana news, Director Jorge S. Mesquita acquired 545 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was bought at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the purchase, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.32% of the stock is owned by insiders.

Institutional Trading of Humana

Several large investors have recently added to or reduced their stakes in HUM. Rakuten Securities Inc. acquired a new position in Humana in the fourth quarter worth $25,000. Gradient Investments LLC lifted its position in Humana by 200.0% during the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after buying an additional 40 shares in the last quarter. Cetera Trust Company N.A bought a new stake in Humana during the 4th quarter worth about $28,000. Private Wealth Management Group LLC acquired a new stake in Humana in the 4th quarter valued at about $32,000. Finally, Nvwm LLC raised its stake in shares of Humana by 41.0% in the third quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock worth $42,000 after acquiring an additional 25 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.